Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Novel Drug Doubles PFS in Heavily Pretreated, HR-Positive Breast Cancer

(MedPage Today) -- Patients with heavily pretreated hormone receptor (HR)-positive breast cancer lived twice as long without disease progression with the novel antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), a randomized trial...

Novel Drug Doubles PFS in Heavily Pretreated, HR-Positive Breast Cancer

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Monday 26 October →